타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cosentyx (secukinumab) |
Overview Company | Novartis |
Overview Modality | ANTIBODY |
Overview Target | IL-17A |
Overview Indication | Psoriasis, PsA, AS, nr-axSpA, HS |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres |
Positioning Known limitation | bypassed its classic signal adaptor and directly interacted with the calcium-binding protein S100A9 |
MoA Mechanism | Secukinumab binds IL-17A and prevents interaction with IL-17RA/RC receptor complex, inhibiting keratinocyte and synovial inflammation driven by Th17 pathway. |
MoA Biomarker | PASI, ASAS response, radiographic progression in SpA. |
Toxicology Species | Mouse |
Toxicology Major finding | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. |
Toxicology CRS | N/A |
Clinical Safety signal | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Cosentyx (secukinumab) |
Overview Company | Novartis |
Overview Modality | ANTIBODY |
Overview Target | IL-17A |
Overview Indication | Psoriasis, PsA, AS, nr-axSpA, HS |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Novel approaches, including tolerogenic DC therapy and neuroimmune modulation, hold promise for refining treatment and addres |
Positioning Known limitation | bypassed its classic signal adaptor and directly interacted with the calcium-binding protein S100A9 |
MoA Mechanism | Secukinumab binds IL-17A and prevents interaction with IL-17RA/RC receptor complex, inhibiting keratinocyte and synovial inflammation driven by Th17 pathway. |
MoA Biomarker | PASI, ASAS response, radiographic progression in SpA. |
Toxicology Species | Mouse |
Toxicology Major finding | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. |
Toxicology CRS | N/A |
Clinical Safety signal | Nasopharyngitis, candidiasis (mucocutaneous), neutropenia; IBD caution in label. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교